{"id":"https://openalex.org/W2327696366","doi":"https://doi.org/10.3851/imp2920","title":"Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects","display_name":"Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects","publication_year":2014,"publication_date":"2014-05-01","ids":{"openalex":"https://openalex.org/W2327696366","doi":"https://doi.org/10.3851/imp2920","mag":"2327696366","pmid":"https://pubmed.ncbi.nlm.nih.gov/25470746"},"language":"en","primary_location":{"id":"doi:10.3851/imp2920","doi":"https://doi.org/10.3851/imp2920","is_oa":true,"landing_page_url":"https://doi.org/10.3851/imp2920","pdf_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2920","source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2920","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087881684","display_name":"Matt S. Anderson","orcid":"https://orcid.org/0009-0005-3940-7056","observed_orcids":["https://orcid.org/0009-0005-3940-7056"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Matt S Anderson","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110579289","display_name":"Jocelyn Gilmartin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jocelyn Gilmartin","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038185249","display_name":"Caroline Cilissen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121359","display_name":"MSD (Belgium)","ror":"https://ror.org/02j4p4h77","country_code":"BE","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210121359"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Caroline Cilissen","raw_affiliation_strings":["Merck, Sharp & Dohme (Europe) Inc., Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck, Sharp & Dohme (Europe) Inc., Brussels, Belgium","institution_ids":["https://openalex.org/I4210121359"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112425516","display_name":"Inge De Lepeleire","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121359","display_name":"MSD (Belgium)","ror":"https://ror.org/02j4p4h77","country_code":"BE","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210121359"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Inge De Lepeleire","raw_affiliation_strings":["Merck, Sharp & Dohme (Europe) Inc., Brussels, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck, Sharp & Dohme (Europe) Inc., Brussels, Belgium","institution_ids":["https://openalex.org/I4210121359"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113565004","display_name":"Luc M. Van Bortel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801227569","display_name":"Ghent University Hospital","ror":"https://ror.org/00xmkp704","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2801227569"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Luc Van Bortel","raw_affiliation_strings":["University Hospital Ghent, Drug Research Unit, Ghent, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital Ghent, Drug Research Unit, Ghent, Belgium","institution_ids":["https://openalex.org/I2801227569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034116722","display_name":"Marissa Fallon Dockendorf","orcid":"https://orcid.org/0000-0002-6341-0221","observed_orcids":["https://orcid.org/0000-0002-6341-0221"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marissa F Dockendorf","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012970737","display_name":"Ernestina Tetteh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ernestina Tetteh","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025086413","display_name":"June K Ancona","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"June K Ancona","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026265919","display_name":"Rachael Liu","orcid":"https://orcid.org/0000-0001-6033-4510","observed_orcids":["https://orcid.org/0000-0001-6033-4510"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachael Liu","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100633195","display_name":"Ying Guo","orcid":"https://orcid.org/0000-0003-2929-5562","observed_orcids":["https://orcid.org/0000-0003-2929-5562"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ying Guo","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111938300","display_name":"John A. Wagner","orcid":"https://orcid.org/0000-0002-0636-5006","observed_orcids":["https://orcid.org/0000-0002-0636-5006","https://orcid.org/0000-0003-0038-8511"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John A Wagner","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022689608","display_name":"Joan R. Butterton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joan R Butterton","raw_affiliation_strings":["Merck & Co., Inc., Kenilworth, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Kenilworth, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5087881684"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":{"value":2800,"currency":"USD","value_usd":2800},"apc_paid":null,"fwci":3.5408,"has_fulltext":true,"cited_by_count":82,"citation_normalized_percentile":{"value":0.92852365,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"20","issue":"4","first_page":"397","last_page":"405"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/doravirine","display_name":"doravirine","score":0.9909999966621399},{"id":"https://openalex.org/keywords/hiv-1-reverse-transcriptase-inhibitors","display_name":"HIV-1 reverse transcriptase inhibitors","score":0.8349999785423279},{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.8939999938011169},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9940000176429749},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8610000014305115},{"id":"https://openalex.org/keywords/midazolam","display_name":"midazolam","score":0.7070000171661377},{"id":"https://openalex.org/keywords/food-effect","display_name":"food effect","score":0.6159999966621399},{"id":"https://openalex.org/keywords/accumulation","display_name":"accumulation","score":0.3440000116825104},{"id":"https://openalex.org/keywords/steady-state-pharmacokinetics","display_name":"steady-state pharmacokinetics","score":0.6790000200271606},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6570000052452087},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.722000002861023},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7120000123977661},{"id":"https://openalex.org/keywords/oxidative-metabolism","display_name":"oxidative metabolism","score":0.6679999828338623},{"id":"https://openalex.org/keywords/antiretroviral-therapy","display_name":"antiretroviral therapy","score":0.6460000276565552}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8580296039581299},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.7674775123596191},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6983163952827454},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5073356032371521},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.4834771752357483},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4718964993953705},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.41661956906318665},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.37198418378829956},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.21201464533805847},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.2023218870162964},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.1523781716823578},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.10755741596221924},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.09099790453910828},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002853","descriptor_name":"Chromatography, Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008874","descriptor_name":"Midazolam","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008874","descriptor_name":"Midazolam","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011728","descriptor_name":"Pyridones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D053719","descriptor_name":"Tandem Mass Spectrometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3851/imp2920","doi":"https://doi.org/10.3851/imp2920","is_oa":true,"landing_page_url":"https://doi.org/10.3851/imp2920","pdf_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2920","source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},{"id":"pmid:25470746","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25470746","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral therapy","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.3851/imp2920","doi":"https://doi.org/10.3851/imp2920","is_oa":true,"landing_page_url":"https://doi.org/10.3851/imp2920","pdf_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2920","source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320321625","display_name":"Daiichi-Sankyo","ror":"https://ror.org/027y26122"},{"id":"https://openalex.org/F4320327235","display_name":"Servier","ror":"https://ror.org/034e7c066"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2327696366.pdf","grobid_xml":"https://content.openalex.org/works/W2327696366.grobid-xml"},"referenced_works_count":4,"referenced_works":["https://openalex.org/W2035031389","https://openalex.org/W2071059013","https://openalex.org/W2132185205","https://openalex.org/W2147093183"],"related_works":["https://openalex.org/W3071645158","https://openalex.org/W2965906673","https://openalex.org/W2416139320","https://openalex.org/W2883591825","https://openalex.org/W2528141927","https://openalex.org/W2551398029","https://openalex.org/W2945178990","https://openalex.org/W2565343787","https://openalex.org/W2601464367","https://openalex.org/W2937154946"],"abstract_inverted_index":{"BACKGROUND:":[0],"Doravirine":[1,25,265,299],"is":[2,35,266],"a":[3,197,292,311],"novel":[4],"non-nucleoside":[5],"inhibitor":[6],"of":[7,55,72,99,109,124,136,151,161,192,227,296,307],"HIV-1":[8],"reverse":[9],"transcriptase":[10],"with":[11,131,140,155,196,202,215,291],"potent":[12],"activity":[13],"against":[14],"wild-type":[15],"virus":[16],"(95%":[17],"inhibitory":[18],"concentration":[19,122,181],"19":[20],"nM,":[21],"50%":[22],"human":[23],"serum).":[24],"has":[26],"low":[27],"potential":[28],"to":[29,209,274,281,288,310],"cause":[30],"drug-drug":[31],"interactions":[32],"since":[33],"it":[34],"primarily":[36],"eliminated":[37],"by":[38,225],"oxidative":[39],"metabolism":[40],"and":[41,53,178,212,248,277],"does":[42],"not":[43],"inhibit":[44],"or":[45,76,86,246,253],"significantly":[46],"induce":[47],"drug-metabolizing":[48],"enzymes.":[49],"METHODS:":[50],"The":[51,119],"pharmacokinetics":[52,108],"safety":[54],"doravirine":[56,73,83,100,125,195,228,249],"were":[57,262],"investigated":[58],"in":[59,64,163,205,218,270],"two":[60],"double-blind,":[61],"dose-escalation":[62],"studies":[63],"healthy":[65],"males.":[66],"Thirty-two":[67],"subjects":[68,81],"received":[69,82],"single":[70,271],"doses":[71,272,279],"(6-1,200":[74],"mg)":[75,85],"matching":[77,87],"placebo":[78,88],"tablets;":[79],"40":[80],"(30-750":[84],"tablets":[89],"once":[90,152,284],"daily":[91,153,285],"for":[92,103,286],"10":[93,289],"days.":[94],"In":[95],"addition,":[96],"the":[97,110,164,167,172,305],"effect":[98],"(120":[101],"mg":[102,194,276,283],"14":[104],"days)":[105],"on":[106],"single-dose":[107,141],"CYP3A":[111],"substrate":[112],"midazolam":[113],"was":[114,126,145,200,222,238],"evaluated":[115],"(10":[116],"subjects).":[117],"RESULTS:":[118],"maximum":[120],"plasma":[121,168,180],"(Cmax)":[123],"achieved":[127,146],"within":[128],"1-5":[129],"h":[130,214],"an":[132],"apparent":[133,240],"terminal":[134],"half-life":[135],"12-21":[137],"h.":[138],"Consistent":[139],"pharmacokinetics,":[142],"steady":[143,301],"state":[144,302],"after":[147],"approximately":[148],"7":[149],"days":[150],"administration,":[154],"accumulation":[156],"ratios":[157],"(day":[158],"10/day":[159],"1)":[160],"1.1-1.5":[162],"area":[165],"under":[166],"concentration-time":[169],"curve":[170],"during":[171],"dosing":[173],"interval":[174],"(AUC0-24":[175],"h),":[176],"Cmax":[177],"trough":[179],"(C24":[182],"h).":[183],"All":[184],"dose":[185],"levels":[186],"produced":[187],"C24":[188,213],"h>19":[189],"nM.":[190],"Administration":[191],"50":[193],"high-fat":[198],"meal":[199],"associated":[201],"slight":[203],"elevations":[204],"AUC":[206],"time":[207],"zero":[208],"infinity":[210],"(AUC0-\u221e)":[211],"no":[216,239],"change":[217],"Cmax.":[219],"Midazolam":[220],"AUC0-\u221e":[221],"slightly":[223,303],"reduced":[224,304],"coadministration":[226],"(geometric":[229],"mean":[230],"ratio":[231],"0.82,":[232],"90%":[233],"CI":[234],"0.70,":[235],"0.97).":[236],"There":[237],"relationship":[241],"between":[242],"adverse":[243],"event":[244],"frequency":[245],"intensity":[247],"dose.":[250],"No":[251],"rash":[252],"significant":[254],"central":[255],"nervous":[256],"system":[257],"events":[258],"other":[259],"than":[260],"headache":[261],"reported.":[263],"CONCLUSIONS:":[264],"generally":[267],"well":[268],"tolerated":[269],"up":[273,280,287],"1,200":[275],"multiple":[278],"750":[282],"days,":[290],"pharmacokinetic":[293],"profile":[294],"supportive":[295],"once-daily":[297],"dosing.":[298],"at":[300],"exposure":[306],"coadministered":[308],"midazolam,":[309],"clinically":[312],"unimportant":[313],"extent.":[314]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":15},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":4}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}